Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial looking at rucaparib for solid tumours including ovarian cancer
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at a new drug called rucaparib for people who have solid tumours including ovarian cancer that has grown into surrounding tissue or spread to another part of the body. This trial is in 2 parts. The 1st part included people with any type of
More about this trial
Doctors usually treat ovarian cancer that has spread with surgery and chemotherapy.
Rucaparib is a type of drug known as a PARP inhibitor. PARP is an enzyme that helps damaged cells to repair themselves. If PARP is blocked, cancer cells may not be able to repair themselves.
You can have rucaparib as an injection into a vein or as a tablet. In this trial you will have rucaparib as a tablet.
The aims of this trial are to find out
- The highest dose of rucaparib that you can safely have as a tablet (in the 1st part of the trial). This dose has been chosen for Part 2 of this trial
- More about the side effects and how rucaparib works in the body
- How well rucaparib works
Who can enter
This trial is in 2 parts. The 1st part was for people who had any type of solid tumour that had come back or had spread to another part of the body. Please note – this part of the trial is now complete.
The 2nd part of the trial is for women who have ovarian cancer with a change (
For the extended 2nd part of this trial you must
- Have ovarian cancer with a fault in the BRCA 1 or BRCA 2 gene
- Have had at least 3 types of chemotherapy
- Have cancer that has currently come back or had come back within at least 6 months after your first chemotherapy tretament
As well as the above
- You have satisfactory blood test results
- Your heart works well enough - your doctor will test for this
- You are well enough to carry out all your normal activities, apart from heavy physical work (performance status of 0 or 1)
- You are willing to use reliable contraception during the trial and for 6 months afterwards if there is any chance you or your partner could become pregnant
- You are at least 18 years old
You cannot enter either part of this trial if you
- Have cancer that has spread to your brain or spinal cord and is causing symptoms – you may take part if you have no symptoms and the cancer has been stable for the last month
- Have had another PARP inhibitor apart from iniparib
- Have had another anti cancer treatment in the last 2 weeks
- Have had an experimental drug as part of another clinical trial in the last 2 weeks
- Have had surgery in the last 5 days
- Have a serious heart problem
- Have another cancer uless it was successfully treated more than 6 monhts ago
- Have problems with your
digestive systemthat would make it difficult for you to absorb tablets
- Are taking medications that could affect the way rucaparib works – your doctor can advise about this
- Are HIV, hepatitis B or hepatitis C positive
- Have any other condition that could affect you taking part in this trial
- Are pregnant or breastfeeding
This phase 1/2 trial is in 2 parts.
Part 1 recruited people who had solid tumours. The first few people taking part had a low dose of rucaparib. If they didn’t have any serious side effects, the next few had a higher dose of rucaparib. And so on, until they found the best dose to give. This is called a dose escalation study.
In part 1 the researchers also found out if food could affect how much rucaparib your body absorbed. To do this they asked a small number of people on a day when they attended the clinic not to eat for at least 10 hours before and 2 hours after taking their rucaparib. A week later they fasted for at least 10 hours and then ate a high calorie, high fat breakfast.
Part 2 will recruit about 80 people with ovarian cancer that is locally advanced or has spread to another part of the body. They will have rucaparib at the highest safe dose found in part 1. In this part of the study, the researchers want to learn more about the side effects and whether rucaparib helps people with ovarian cancer that is locally advanced or has spread to another part of the body.
You take rucaparib tablets twice a day. You can take rucaparib with or without food.
As long as you don’t have bad side effects, you can carry on taking rucaparib for as long as your doctor thinks it is still helping you.
For a week before starting rucaparib, and while taking it, you must not eat grapefruit, anything containing grapefruit, drink grapefruit juice or take the herbal supplement St John’s Wort. This is because they can affect the way rucaparib works in your body.
You will see the doctor and have some tests before you start treatment. The tests include
During, and after treatment you see the doctor regularly and have the same tests. You have a CT scan or MRI scan every 6 to 9 weeks.
The trial team will continue to monitor you to see if your cancer comes back.
Rucaparib is a new drug and there may be side effects we don’t know about yet. The most commonly reported side effects include
- A drop in blood cells causing an increased risk of infection, bleeding or bruising
- Feeling or being sick
- Diarrhoea or constipation
- Loss of appetite and changes to taste
- A change in the way your liver or kidneys work
- An increase in your cholesterol levels
Your doctor will talk to you about the possible side effects before you agree to take part in the study.
How to join a clinical trial
Dr Rebecca Kristeleit
Clovis Oncology Inc
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer